SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EDAP TMS SA - EDAP

NEW YORK, July 31, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EDAP TMS SA ("EDAP" or the "Company") (NASDAQ: EDAP).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 237.

The investigation concerns whether EDAP and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. 

On July 28, 2014, the Company announced that Food and Drug Administration ("FDA") staff questioned EDAP's safety and effectiveness data because the Company compared patients in two different studies to gather evidence, rather than a head-to-head trial. The investigation also relates to the FDA's July 30, 2014, announcement that the panel convened to review EDAP's submission unanimously found that EDAP had failed to demonstrate the efficacy of its product or that it had demonstrated that the benefits of the device outweighed its risk. 

On this news, shares of EDAP fell $1.57 per share to $1.85, or more than 45.91%, in intraday trading on July 31, 2014.

The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected] 

SOURCE Pomerantz LLP